PMID- 9050746
OWN - NLM
STAT- MEDLINE
DCOM- 19970624
LR  - 20061115
IS  - 1043-4666 (Print)
IS  - 1043-4666 (Linking)
VI  - 8
IP  - 12
DP  - 1996 Dec
TI  - Cytokines involving gp130 in signal transduction suppressed growth of a mouse 
      hybridoma cell line and enhanced its antibody production.
PG  - 889-94
AB  - Three cytokines, interleukin 6 (IL-6), leukaemia inhibitory factor (LIF), and 
      oncostatin M (OSM), that bind to composite receptors including a common signal 
      transducer gp130 suppressed proliferation of a mouse B-cell hybridoma cell line 
      2E3-O cultured in serum-free medium, while they enhanced antibody production of 
      the cells. The specific growth rate of the cells reduced from 1.0/day for control 
      to 0.6/day for the cultures supplemented with IL-6, LIF, or OSM at 1, 4, or 2 
      ng/ml, respectively. The antibody productivity increased five-fold when the cells 
      were cultured with IL-6, LIF, or OSM at 1, 25, or 20 ng/ml, respectively. 
      Transforming growth factor beta1(TGF-beta1) similarly suppressed growth of the 
      cells at the concentration of 5 ng/ml, while it did not enhance the antibody 
      production. Cell cycle analysis revealed that IL-6 induced the cells to be 
      arrested at G1 phase of the cell cycle more intensively than TGF-beta1, 
      indicating that IL-6 and TGF-beta1 suppressed the growth through mutually 
      different mechanisms. As a whole, this work suggests that gp130, which is 
      commonly involved in each receptor for IL-6, LIF, and OSM, transduces signals for 
      suppressing proliferation and possibly for enhancing antibody production in the 
      hybridoma cells.
FAU - Terada, S
AU  - Terada S
AD  - Department of Chemistry and Biotechnology, Graduate School of Engineering, The 
      University of Tokyo, Bunkyo-ku, Japan.
FAU - Suzuki, E
AU  - Suzuki E
FAU - Ueda, H
AU  - Ueda H
FAU - Makishima, F
AU  - Makishima F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Antigens, CD)
RN  - 0 (Growth Inhibitors)
RN  - 0 (Il6st protein, mouse)
RN  - 0 (Interleukin-6)
RN  - 0 (Leukemia Inhibitory Factor)
RN  - 0 (Lif protein, mouse)
RN  - 0 (Lymphokines)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Osm protein, mouse)
RN  - 0 (Peptides)
RN  - 0 (Transforming Growth Factor beta)
RN  - 106956-32-5 (Oncostatin M)
RN  - 133483-10-0 (Cytokine Receptor gp130)
SB  - IM
MH  - Animals
MH  - Antibody Formation/*drug effects
MH  - Antigens, CD/*immunology
MH  - Cell Cycle
MH  - Cell Division/drug effects
MH  - Cytokine Receptor gp130
MH  - Drug Synergism
MH  - G1 Phase
MH  - Growth Inhibitors/*pharmacology
MH  - Hybridomas
MH  - Interleukin-6/*pharmacology
MH  - Leukemia Inhibitory Factor
MH  - Lymphokines/*pharmacology
MH  - Membrane Glycoproteins/*immunology
MH  - Mice
MH  - Oncostatin M
MH  - Peptides/*pharmacology
MH  - *Signal Transduction
MH  - Transforming Growth Factor beta/pharmacology
MH  - Tumor Cells, Cultured
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - S1043-4666(96)90119-2 [pii]
AID - 10.1006/cyto.1996.0119 [doi]
PST - ppublish
SO  - Cytokine. 1996 Dec;8(12):889-94. doi: 10.1006/cyto.1996.0119.